The COVID-19 pandemic has had a negative impact on cardiovascular disease (CVD)
prevention. Targeted CVD prevention initiatives will directly reduce health
inequalities and are highly effective at reducing stroke, myocardial infarction (MI)
and other adverse cardiovascular events1. Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a major cause of stroke. People with AF have five times the risk of a stroke compared to those with a normal heart rhythm. AF is responsible for around 20–25% of all strokes in the UK and these strokes tend to be more severe2, and it is estimated there could be another half a million people in the UK with undiagnosed AF3.
At the same time, with an estimated incidence rate of 1–2 per 1,000 of the population in the UK, venous thromboembolism (VTE) is a significant cause of mortality and disability in England with thousands of deaths directly attributed to it each year. One in twenty people will have VTE during their lifetime. VTE therefore poses a significant burden on the NHS, with an estimated annual cost of £165.1 million4
Current NICE guidelines recommend the use of anticoagulants such as warfarin and the direct oral anticoagulants (DOACs) for the prevention of stroke related to non-valvular atrial fibrillation (NVAF) and for the treatment of VTE5.
This patient case-based webinar will explore how anticoagulation can be optimised to improve patient outcomes in NVAF and VTE. You will have the opportunity to look at practical implementation of relevant guidelines on the detection and management of high-risk cardiovascular conditions, with the goal of improving quality of care for patients at risk of CV events. The webinar then explores how to put the Detect, Protect and Perfect National programme into practice, to tackle the issue of AF-related stroke. The webinar further provides practical guidance on the management of patients with acute VTE, risk of VTE recurrence and for secondary prevention of VTE in patients with cancer-associated thrombosis (CAT).
Reference 1: British Heart Foundation UK Factsheet. Last accessed January 2021. British Heart Foundation. https://www.bhf.org.uk/-/media/files/research/heart-statistics/bhf-cvd-statistics-uk-factsheet.pdf
Reference 2: Improving detection and management of AF. Last accessed January 2021. Oxford academic health science network. https://www.oxfordahsn.org/our-work/adopting-innovation/improving-detection-and-management-of-atrial-fibrillation-af/
Reference 3: Atrial Fibrillation: Information and Resources. Last accessed January 2021. Stroke Association. https://www.stroke.org.uk/professionals/atrial-fibrillation-information-and-resources
Reference 4: All Party Parliamentary Thrombosis Group Annual Review 2019. Last accessed January 2021. APPT Group. https://www.anticoagulationuk.org/downloads/APPTG%20Annual%20Review%202019.pdf
Reference 5: Anticoagulants, including direct acting oral anticoagulants (DOACs). Last accessed January 2021. NICE. https://www.nice.org.uk/advice/ktt16/chapter/Evidence-context
Professor Ahmet Fuat Professor Ahmet Fuat was a GP in Darlington, County Durham for 37 years, serving as CVD and Research Lead for the Darlington Primary Care Network and GP Federation. He became Medical Director at Oberoi Consulting in 2023 and will soon begin an Honorary Consultant Lipidologist/GPSI role with the diabetes and endocrinology team at County Durham and Darlington Foundation Trust.
A GPSI in Cardiology for over 25 years, he gained a Postgraduate Diploma in Cardiology from Bradford University with distinction and later tutored on the programme, teaching in heart failure (HF), valve disease, atrial fibrillation and ischaemic heart disease. In 2002, he helped establish the UK’s first one-stop diagnostic and integrated HF clinic. His PhD in HF diagnosis and management, including work on natriuretic peptides, produced influential publications and led to an Honorary Professorship at Durham University. He has contributed to NICE and ESC cardiovascular guidelines and the RCGP CKD/AKI toolkit.
Professor Fuat is the immediate past President of the Primary Care Cardiovascular Society (PCCS), now its Education and Research Lead, and serves as Lipid and HF Primary Care Lead for the North East and North Cumbria Academic Health Science Network. He is a member of the NHSE CVD Prevention Clinical Leadership Group and expert advisory groups for HF and heart valve disease, and a founder member of CaReMe UK.
Committed to medical education, he lectures widely, serves on editorial boards, and reviews for major cardiovascular journals. His contributions to community cardiology have been recognised with Fellowships from the RCGP, RCP London, RCP Edinburgh and the PCCS. At Oberoi, he oversees clinical development of digital disease-management platforms and mentors HF specialist nurses and clinical pharmacists.
This webinar will NOT be recorded due to the presentation being the Intellectual Property of the speakers.
The Zoom link to join the event will be emailed to the email address you booked with. This may be received into your spam/junk inboxes, please check.
If you cannot locate the Zoom link, please email webinar@mediconf.co.uk for assistance.
We no longer offer the option to dial in using your phone due to the excessive fees charged.
Find us on LINKEDIN
© Copyright 2007 - 2026 MediConf ©, Inc. All Rights Reserved ©
Registered Office: MediConf Uk c/o LCW Consulting, SWP, Suffolk House, George Street, Croydon, Surrey, CR0 0YN
Registered in England No. 09705397. Company registered in England and Wales. VAT Registration Number: 219014242
Telephone: 01444 414 264
Website design & development by Dual Media Ltd
This site is intended for use by UK healthcare professionals.
Please select the appropriate option below.